EN DE
Watch Vitura Health Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vitura Health Ltd (VIT) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Vitura Health Ltd stock A$0.02, price A$0.02, that is 17.2% below the price, quality 31 out of 100. Rating: overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000266801

VH Vitura Health Ltd logo Thin data Nov 4, 2026

Vitura Health Ltd

VIT · AU
Expensive, weak quality

Our calculation puts a fair price 17% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +43.3 %/yr in AUD)
10.0% dividend yield · Watch coverage
Fair value A$0.0166 · Overvalued
Quality 31/100
Loss-making · -3.4% net margin (TTM)
Negative free cash flow
Trails peers (3/11)
Narrow moat 14/100 · thin data
Thin data
Watch Vitura Health Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.9353 A$0.0160 Fair Value A$0.0166 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range A$0.0160 – A$0.9353 · the A$0.0200 price screens above the A$0.0166 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Vitura Health in your weekly email

Every Wednesday you see whether Vitura Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services.

Show moreShow less

The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a therapy clinic that offers telehealth consultations.

It also offers psychedelics under the Cortexa brand; Adaya which provides hybrid formulations and Australian-cultivated products; candor medical that provides care to patients; and inscape, which offers crafted formulations for individual needs.

The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. Vitura Health Limited was incorporated in 2018 and is based in South Yarra, Australia.

Stock analysis

Vitura Health Ltd (VIT) currently trades at A$0.0200, while our model-based Fair Value estimate is A$0.0166, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Vitura Health Ltd reported revenue of A$131M in FY2026 versus A$67.0M in FY2022, a compound +18.3%/yr. Reported net income was −A$4.4M in FY2026.

Key figures

Market cap A$13.3M (≈ $9.1M) Micro · P/S ratio 0.09 · EPS (TTM) A$−0.0100 · Dividend yield 10.0% · Net margin −3.4% · Return on equity −9.7% · Return on assets (EBIT) 15.3% (5-year average) · Operating margin −3.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −17%, VIT screens cheaper than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA n/a A$0.0100 A$0.0200 57
NCAV (Graham) n/a n/a A$0.0100 51
All 2 models by family
Multiples
EV/EBITDA n/a A$0.0100 A$0.0200 57
Asset-Based
NCAV (Graham) n/a n/a A$0.0100 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 58
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 15
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.3%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+168.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.8% (2021) → −1.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

VIT screens overvalued: fair value 17% below the price. Compare with Merck KGaA →

Compare Vitura Health Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −17.0% · Below median
Profitability
Return on assets −5.7% · Bottom 25%
Net margin (12 months) −3.4% · Bottom 25%
Operating margin (12 months) −3.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 3.1% · Below median
Dividend yield (12 months) 10.0% · Top 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.30× · Cheapest 25%
P/S (12 months) 0.10× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 15
FUTURE (revenue growth)16 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)92 · sector 96
DIVIDEND (yield)100 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs VIT
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs VIT
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs VIT
Haleon plc HLN $9.14 $8.61 −6% vs VIT
Merck KGaA MRK €148.75 €109.18 −27% vs VIT
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs VIT
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs VIT
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs VIT
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs VIT
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs VIT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vitura Health Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vitura Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/VIT

Frequently asked questions

Is Vitura Health Ltd (VIT) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0166 versus a price of A$0.0200, about 17% lower (overvalued).
What is the fair value of VIT?
Our model-based fair value for Vitura Health Ltd is A$0.0166 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0200.
What is the quality score of VIT?
Vitura Health Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vitura Health Ltd (VIT)?
Our model-based price target is the fair value of A$0.0166 (as of Nov 4, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Vitura Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0166, about 17% lower versus a price of A$0.0200 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Vitura Health Ltd (VIT)?
Vitura Health Ltd reported trailing-twelve-month revenue of about A$131M (latest available figure, as of Nov 4, 2026).
Does Vitura Health Ltd pay a dividend?
Vitura Health Ltd currently shows a dividend yield of 10.00% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Vitura Health Ltd (VIT) and when is the ex-dividend date?
Vitura Health Ltd pays a dividend of A$0.002 per share a year, a dividend yield of 10.0%. The last ex-dividend date was Sep 5, 2025. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Vitura Health Ltd (VIT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vitura Health Ltd it is A$0.0166 per share (as of Nov 4, 2026), against a price of A$0.0200. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Vitura Health Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, VIT trades above its calculated fair value: price A$0.0200, fair value A$0.0166, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIT?
No. The price is what the market pays today (A$0.0200); the fair value is what the company's own numbers justify (A$0.0166). For Vitura Health Ltd the two are A$0.0034 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vitura Health Ltd worth?
The market values Vitura Health Ltd at about A$13.3M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0200; our models calculate a fair value of A$0.0166 per share.
How solid is the balance sheet of Vitura Health Ltd (VIT)?
Balance-sheet figures for Vitura Health Ltd (as of Nov 4, 2026): return on equity −9.7%, debt of 0.16 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is VIT from its 52-week high?
Vitura Health Ltd trades at A$0.0200, about 70% below its 52-week high of A$0.0660 and 25% above the low of A$0.0160 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0166 is for.
Which stocks are comparable to Vitura Health Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vitura Health Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0200, calculated fair value A$0.0166 (−17%), Quality Score 31/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VIT calculated?
We run Vitura Health Ltd through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0166 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Vitura Health Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vitura Health Ltd (VIT)?
The closing price on Nov 9, 2026 was A$0.0200. Our model-based fair value is A$0.0166, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vitura Health Ltd right now?
Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vitura Health Ltd

How large is the market capitalisation of Vitura Health Ltd (VIT)?
The market capitalisation of Vitura Health Ltd is A$13.3M (≈ $9.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vitura Health Ltd (VIT)?
The price-to-sales ratio of Vitura Health Ltd is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vitura Health Ltd (VIT)?
Earnings per share at Vitura Health Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Vitura Health Ltd (VIT)?
The dividend yield of Vitura Health Ltd is 10.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vitura Health Ltd (VIT)?
The net margin of Vitura Health Ltd is −3.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vitura Health Ltd (VIT)?
The return on equity (ROE) of Vitura Health Ltd is −9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vitura Health Ltd (VIT)?
On an EBIT basis the return on assets of Vitura Health Ltd is 15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vitura Health Ltd (VIT)?
The operating margin of Vitura Health Ltd is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vitura Health Ltd (VIT)?
Revenue at Vitura Health Ltd is growing +3.1% versus a year earlier (3y avg +3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vitura Health Ltd (VIT)?
Earnings per share at Vitura Health Ltd are growing +515% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vitura Health Ltd (VIT) generate?
The free cash flow of Vitura Health Ltd is −A$217K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vitura Health Ltd (VIT) carry?
The net debt of Vitura Health Ltd is A$11.0M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vitura Health Ltd in the live analysis

One click puts Vitura Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.